JP Morgan Maintains Overweight on Aramark, Lowers Price Target to $69
JP Morgan analyst Andrew Steinerman maintains Aramark (NYSE:ARMK) with a Overweight and lowers the price target from $70 to $69.
Follow the latest ARAMARK (ARMK) news and market headlines alongside the live ARMK price. Stay informed on what's moving ARMK.
JP Morgan analyst Andrew Steinerman maintains Aramark (NYSE:ARMK) with a Overweight and lowers the price target from $70 to $69.
Aramark missed Q4 earnings and revenue estimates, issued below-consensus FY27 guidance, while analysts cut two price targets and UBS raised its target.
UBS analyst Joshua Chan maintains Aramark (NYSE:ARMK) with a Buy and raises the price target from $65 to $68.
Morgan Stanley analyst Toni Kaplan maintains Aramark (NYSE:ARMK) with a Equal-Weight and lowers the price target from $63 to $61.
Baird analyst Andrew Wittmann maintains Aramark (NYSE:ARMK) with a Outperform and lowers the price target from $69 to $65.
Aramark reported strong fiscal 2026 results with 10% organic revenue growth to $20.1 billion and a 97% client retention rate driving 6.8% net new business growth. The company's specialized Nexus platform is expected to contribute $500 million in revenue in fiscal 2027 by serving data centers. Aramark reduced leverage to a 20-year low of 2.7x, enabling a 17% dividend increase and a new $1 billion share repurchase program. Management projects 9-10% organic revenue growth for fiscal 2027.
Despite 12% organic revenue growth and a new $1B share repurchase plan, Aramark (ARMK) stock fell on a Q4 earnings miss, weak 2027 outlook.
Aramark (NYSE:ARMK) is looking for FY2027 Adj EPS of $2.68-$2.79 vs $2.81 analyst estimate..
Aramark (NYSE:ARMK) reported quarterly earnings of $0.71 per share which missed the analyst consensus estimate of $0.75 by 5.33 percent. This is a 24.56 percent increase over earnings of $0.57 per share from the same
Market sentiment slipped deeper into Fear at 39. Stocks closed mixed as Nasdaq fell 0.91%, though all major indexes posted weekly gains.
Tyson Foods and Aramark report earnings before Monday’s open; AECOM and Baidu after close. Espey posts weak results; shares slip.
Aramark reports Q4 earnings Nov. 16; analysts expect EPS of $0.75 and revenue of $5.29B. Analysts raised price targets to $69-$71.
Gainers Digital Brands Group (NASDAQ:DBGI) stock increased by 5.1% to $0.21 during Thursday's after-market session. Park Ha Biological Tech (NASDAQ:BYAH) stock increased by 4.78% to $1.54. The company's market
Arcos Dorados reported Q3 2026 earnings of $0.15 per share, beating consensus estimates of $0.13, with revenues of $1.33 billion exceeding expectations. However, the stock has declined 5.5% year-to-date versus the S&P 500's 11.3% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, and operates in the Retail-Restaurants industry which ranks in the bottom 28% of Zacks industries.
Wall Street analysts project Aramark will report Q4 earnings of $0.75 per share, representing a 17.2% year-over-year increase, with revenues expected at $5.27 billion, up 4.3% from the prior year. The consensus EPS estimate has been revised upward by 0.5% in the past 30 days. Key metrics show growth across both FSS United States and FSS International segments, with operating income and adjusted operating income expected to increase significantly compared to the year-ago quarter.
News and data on this page is provided by our partnered third-party news and market data provider, with the original publisher credited on each article. All third-party content reflects the views of the original publisher and does not represent the views of MEXC. Price and market data shown on this page are provided by third-party data providers and may be delayed. MEXC offers trading products related to ARMK, including RealStocks and Stock Futures.
The content on this page is provided for informational purposes only and does not constitute investment, financial, or trading advice. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of any news or market data shown. Trading U.S. stocks and related products involves significant risk, and prices can move sharply in a short period. Past performance does not guarantee future results. Please conduct your own research and assess your financial situation and risk tolerance before making any investment decisions. MEXC is not liable for any losses arising from the use of this information.